Rationalized landscape on protein-based cancer nanomedicine: Recent progress and challenges

IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Zhechen Fan , Haroon Iqbal , Jiang Ni , Naveed Ullah Khan , Shahla Irshad , Anam Razzaq , Mohammad Y. Alfaifi , Serag Eldin I. Elbehairi , Ali A. Shati , Jianping Zhou , Hao Cheng
{"title":"Rationalized landscape on protein-based cancer nanomedicine: Recent progress and challenges","authors":"Zhechen Fan ,&nbsp;Haroon Iqbal ,&nbsp;Jiang Ni ,&nbsp;Naveed Ullah Khan ,&nbsp;Shahla Irshad ,&nbsp;Anam Razzaq ,&nbsp;Mohammad Y. Alfaifi ,&nbsp;Serag Eldin I. Elbehairi ,&nbsp;Ali A. Shati ,&nbsp;Jianping Zhou ,&nbsp;Hao Cheng","doi":"10.1016/j.ijpx.2024.100238","DOIUrl":null,"url":null,"abstract":"<div><p>The clinical advancement of protein-based nanomedicine has revolutionized medical professionals' perspectives on cancer therapy. Protein-based nanoparticles have been exploited as attractive vehicles for cancer nanomedicine due to their unique properties derived from naturally biomacromolecules with superior biocompatibility and pharmaceutical features. Furthermore, the successful translation of Abraxane™ (paclitaxel-based albumin nanoparticles) into clinical application opened a new avenue for protein-based cancer nanomedicine. In this mini-review article, we demonstrate the rational design and recent progress of protein-based nanoparticles along with their applications in cancer diagnosis and therapy from recent literature. The current challenges and hurdles that hinder clinical application of protein-based nanoparticles are highlighted. Finally, future perspectives for translating protein-based nanoparticles into clinic are identified.</p></div>","PeriodicalId":14280,"journal":{"name":"International Journal of Pharmaceutics: X","volume":"7 ","pages":"Article 100238"},"PeriodicalIF":5.2000,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590156724000100/pdfft?md5=2a1875e2e0561c02f64b4fb2ab03e865&pid=1-s2.0-S2590156724000100-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutics: X","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590156724000100","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The clinical advancement of protein-based nanomedicine has revolutionized medical professionals' perspectives on cancer therapy. Protein-based nanoparticles have been exploited as attractive vehicles for cancer nanomedicine due to their unique properties derived from naturally biomacromolecules with superior biocompatibility and pharmaceutical features. Furthermore, the successful translation of Abraxane™ (paclitaxel-based albumin nanoparticles) into clinical application opened a new avenue for protein-based cancer nanomedicine. In this mini-review article, we demonstrate the rational design and recent progress of protein-based nanoparticles along with their applications in cancer diagnosis and therapy from recent literature. The current challenges and hurdles that hinder clinical application of protein-based nanoparticles are highlighted. Finally, future perspectives for translating protein-based nanoparticles into clinic are identified.

Abstract Image

基于蛋白质的癌症纳米医学的合理前景:最新进展与挑战
基于蛋白质的纳米医学在临床上的发展彻底改变了医学专家对癌症治疗的看法。基于蛋白质的纳米颗粒具有独特的性质,源自天然生物大分子,具有优异的生物相容性和药用特性,因此已被开发为极具吸引力的癌症纳米药物载体。此外,Abraxane™(基于紫杉醇的白蛋白纳米颗粒)成功转化为临床应用,为基于蛋白质的癌症纳米药物开辟了一条新途径。在这篇微型综述文章中,我们展示了基于蛋白质的纳米粒子的合理设计和最新进展,以及近期文献中有关它们在癌症诊断和治疗中的应用。文章强调了目前阻碍蛋白质纳米粒子临床应用的挑战和障碍。最后,我们确定了将基于蛋白质的纳米粒子应用于临床的未来前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Pharmaceutics: X
International Journal of Pharmaceutics: X Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
6.60
自引率
0.00%
发文量
32
审稿时长
24 days
期刊介绍: International Journal of Pharmaceutics: X offers authors with high-quality research who want to publish in a gold open access journal the opportunity to make their work immediately, permanently, and freely accessible. International Journal of Pharmaceutics: X authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright. Please check the APC here. The journal is indexed in SCOPUS, PUBMED, PMC and DOAJ. The International Journal of Pharmaceutics is the second most cited journal in the "Pharmacy & Pharmacology" category out of 358 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信